3-Year CheckMate743 outcomes: ringing in immunotherapy for the treatment of malignant pleural mesothelioma
- PMID: 35306158
- DOI: 10.1016/j.annonc.2022.03.004
3-Year CheckMate743 outcomes: ringing in immunotherapy for the treatment of malignant pleural mesothelioma
Conflict of interest statement
Disclosure SC reports advisory role and/or travel compensation: Bristol Myers Squibb Recipient F, Hoffmann-La Roche AG, Pfizer, Boehringer Ingelheim, MSD Oncology, Amphera. EF reports research funding from Grant for Oncology Innovation, Merck Healthcare KGaA, and Fundacion Merck Salud; personal consulting fees or speakers bureau from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daichii Sankyo, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Janssen, Medical Trends, Medscape, MSD, Merck Serono, Peptomyc, PeerVoice, Pfizer, Regeneron, Sanofi, and Takeda; and independent member of the board for Grifols.
Comment on
-
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.Ann Oncol. 2022 May;33(5):488-499. doi: 10.1016/j.annonc.2022.01.074. Epub 2022 Feb 3. Ann Oncol. 2022. PMID: 35124183 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
